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Intervertebral disc herniation (IVDH) is an important pathology in humans and also in 
dogs. While the molecular disease mechanisms are well investigated in humans, little is 
known about the inflammatory mediators in naturally occurring canine IVDH. The objec-
tive of this study was to investigate whether the involved proinflammatory cytokines in 
human IVDH are also key cytokines in canine IVDH and thus to elucidate the suitability of 
the dog as a model for human trials. 59 samples from 25 dogs with surgically confirmed 
thoracolumbar IVDH were collected and classified in three subgroups: herniated (H), 
affected non-herniated (NH) disc, and adjacent non-affected (NA) disc. Discs from 11 
healthy dogs acted as controls (C). Samples were analyzed for IL-1, IL-6, IL-8, and TNF-
α expression (qPCR/ELISA) as well as cell infiltration and activation of the MAP kinase 
pathways (immunohistochemistry). Gene and protein expression of all key cytokines 
could be detected in IVDH affected dogs. Canine IVDH was significantly associated 
with a higher gene expression of IL-6 (H > C, NH > C) and TNF-α (H > C, NH > C, 
NA > C) and a significant down-regulation of IL-1β (H < C). Dogs with spontaneous 
pain had significantly higher IL-6 mRNA compared to those with pain arising only upon 
palpation. An inter-donor comparison (H and HN relative to NA) revealed a significant 
increase of IL-6 gene expression (H > NA, NH > NA). IL-8 (H > C, NA > C) and TNF-α 
(NH > C) protein levels were significantly increased in diseased dogs while inversely, 
IL-6 protein levels were significantly higher in patients with better clinical outcome. Aside 
from resident IVD cells, mostly monocytes and macrophages were found in extruded 
material, with concomitant activation of extracellular signal-regulated kinase p38 in the 
majority of samples. Dogs with spontaneous IVDH might provide a useful model for 
human disc diseases. Although the expression of key cytokines found in human IVDH 
was also demonstrated in canine tissue, the inflammatory mechanisms accompanying 
canine IVDH diverges partially from humans, which will require further investigations in 
the future. In dogs, IL-6 seems to play an important pathological role and may represent 
a new potential therapeutic target for canine patients.
Keywords: intervertebral disc herniation, inflammatory mediators, il-1β, il-6, il-8, TnF-α, MaP kinase pathway, 
canine animal model
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inTrODUcTiOn
Intervertebral disc degeneration (IVDD) and intervertebral 
disc herniation (IVDH) are considered a major cause of acute 
and chronic low back pain, resulting in a tremendous economic 
burden worldwide (1–4). IVDD is characterized by progressive 
structural and functional changes, including a loss of hydrostatic 
properties of the normally highly hydrated nucleus pulposus 
(NP) (5), as well as increased vascular and neuronal ingrowth that 
is associated with chronic back pain (6). Recent human studies 
have identified proinflammatory cytokines, specifically IL-1β, 
IL-6, IL-8, and TNF-α, as pivotal contributors in the course of 
the pathophysiologic inflammatory cascade of intervertebral 
disc diseases and the development of neuropathic pain through 
irritation of ingrowing nerves (7–28). A herniated disc, pre-
sented as protrusion, extrusion, or sequestration, is a localized 
displacement of disc tissue in the epidural space (29), resulting 
in mechanical compression and chemical irritation of spinal 
nerves, which contribute to ischemia, radicular symptoms, and 
stimulation of the inflammatory cascade (30–39). Alongside of 
heredity (40, 41), multiple factors such as age and smoking are 
involved in the ethiopathogenesis of human IVDD and IVDH 
as well as in the initiation of an inflammatory cascade (42–45). 
Furthermore, obesity was highlighted as an important contribu-
tor to disc pathologies as it not only increases the load on the IVD 
(46–48), but also promotes inflammation via cytokine-release 
from adipocytes and recruited macrophages (49).
Measuring cytokine levels within the diseased tissue can pro-
vide a better understanding of the pathological process. As human 
tissue samples for research—especially as healthy controls—are 
scarce, more complex pathological investigations and testing of 
new therapeutic approaches often require animal experiments 
(50). Currently established models are predominantly based on 
artificially induced disc pathology through mostly invasive manip-
ulations (e.g., stab incision in rodents), which lack similarities to 
the human pathology (51). In contrast, animal models based on 
spontaneously occurring disc pathologies, such as canine IVDH, 
share important similarities to the clinical presentation, pathol-
ogy, lesion morphology, diagnostic, treatment, and recovery with 
human IVDH (50, 52, 53). IVDH in dogs has an incidence of 2% 
of all admissions in referral clinics and occurs predominantly in 
chondrodystrophic breeds, such as Beagle, Dachshund, Shi-Tzu, 
and French Bulldog (54–59). Similar to humans, the prevalence 
of overweight and obesity in dogs is increasing, being as high as 
34% in the US and 25% in the UK (60, 61), with a higher risk 
factor for disc extrusion in dogs with higher body score index 
(62). Despite the potential relevance of canine IVDH as a human 
disease model, little in depth research has been conducted to 
determine its pathological processes in dogs, specifically regard-
ing the role of inflammatory mediators in disease progression 
and pain development. Thus far, existing data indicate that in 
the early phase of canine IVDH, mRNA concentration of IL-6, a 
possible promoter of inflammation and apoptosis of resident glial 
cells, was significantly upregulated, whereas returning to base-
line values in later stages of the disease. In comparison, mRNA 
concentration of IL-8, a potent chemokine and early mediator of 
inflammation, was strongly upregulated in the acute and subacute 
onset of IVDH. A trend of higher TNF-α mRNA concentration 
in acute IVDH could also be shown (63). Controversially, Karli 
et al. demonstrated a downregulation of IL-1β, IL-6, and TNF-α 
mRNA concentrations over the whole course of canine IVDH, 
but highlighted an upregulation of IL-8 mRNA concentration in 
the acute stage of the disease, which decreased when treated with 
non-steroidal anti-inflammatory drugs (64).
Based on the conflicting data found in the current literature, 
the aim of this study was to identify whether the human key 
cytokines are expressed in canine IVDs and to determine patho-
logical alterations in their expression by comparing normal IVDs 
to diseased IVDs with IVDH, with the overall goal to provide 
further information on the validity of the canine disc disease 
model. Concomitantly, we also assessed neurologic function, 
pain status, and clinical outcome in affected dogs.
MaTerials anD MeThODs
Patients, controls, and Tissue samples
Canine disc material was collected from dogs with confirmed 
thoracolumbar IVDH during decompressive surgical procedures 
at our referral institution (November 2013 to February 2015). All 
samples were collected from actual referred patients and not from 
laboratory animals. Herniated (H) and non-herniated (NH) IVD 
samples were both collected from the IVDH: affected level, with 
H = prolapsed part and NH = contained part. Non-affected (NA) 
IVDs were collected from an adjacent spinal level (prophylactic 
disc fenestration). Inclusion criteria for IVDH patients: well-
documented records of onset of clinical signs and pretreatment, 
neurologic findings, diagnosis, course of the disease, ethical 
approval, and signed owner consent.
In addition, healthy control IVDs (C) were collected from 
dogs included in an unrelated animal study or patients without 
any history or signs of spinal disease and without any anti-
inflammatory pretreatment euthanized for other health reasons. 
These samples were directly surgically collected after euthanasia 
within 15 min to avoid potential artifacts in measurements of the 
cytokines (65–67).
In the patient group, breed, age, gender, duration of neurologic 
signs, pretreatment, neurologic grade, severity of pain, localiza-
tion of IVD extrusion, and outcome were recorded. Duration of 
neurologic signs were defined as the time between the onset of 
clinical signs and surgery and was grouped as follows: decom-
pression within the first 24 h after onset of clinical signs (acute), 
between 24 h and 7 days of onset (subacute), or after more than 
7 days (chronic) (68, 69). A complete neurological examination 
was performed at the time of admission, maximally 12 h before 
surgery, at the time at discharge, and at a follow up examination 
between 2 and 4 weeks after discharge. The neurologic condition 
and pain were graded as shown in Table 1 (64, 70, 71).
Diagnostic imaging and surgical 
Treatment
Anesthesia and analgesia were conducted under a standard 
clinical protocol for each patient (44). Magnetic resonance imag-
ing (MRI) of the thoracolumbar spine was performed (Philips 
TaBle 1 | Clinical scoring system.
grade neurological condition Pain
Zero Neither spontaneous pain (vocalization, 
reluctance to move) nor pain on 
palpation of the spine
One Spinal hyperesthesia only No spontaneous pain, but discomfort 
(licking, withdrawal) on palpation of 
the spine
Two Ambulatory paraparesis Spontaneous pain and excessive pain 
(vocalization, aggressive behavior) on 
palpation of the spine
Three Non-ambulatory paraparesis
Four Paraplegia with intact 
nociception
Five Paraplegia without nociception
TaBle 2 | TaqMan primers/probes and sequence accession number.
Target gene assay number accession number
IL-1β Cf02671951_g1 NM_001037971.1
IL-6 Cf02624282_m1 NM_001003301.1
IL-8 Cf02624283_m1 NM_001003200.1
TNF-α Cf02624261_m1 NM_001003244.4
TATA box-binding protein (TBP) Cf02637232_m1 XM_005627735.2
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Panorama HFO, 1.0-T open system, Philips Medical Systems 
Nederland B.V., The Netherlands) to define the IVD extrusion 
site. Immediately after MRI, patients underwent surgery for dis-
cogenic back pain and to decompress the spinal cord. A standard 
hemilaminectomy at the site of extrusion, fenestration of the 
affected and one of the adjacent discs (cranial or caudal) were 
performed, allowing to take three samples of disc material (H, 
NH, and NA). For cytokine identification, removed disc material 
was collected under sterile conditions, snap frozen directly within 
15 s in liquid nitrogen and stored at −80°C until sample prepara-
tion. For immunohistochemical and histological analysis, the 
tissue was fixed in 10% buffered formalin (1–5 days), embedded 
in paraffin, and cut into 5 µm sections.
real-time Pcr (rT-Pcr)
For RNA isolation, each frozen disc sample was transferred into 
a precooled custom-made mortar, filled with liquid nitrogen and 
manually grinded under RNAse free conditions. The frozen tissue 
powder was transferred into 500 µl Trizol (Life Technologies, Van 
Alben Way, CA, USA), homogenized three times for 30 s (Polytron 
PT 2500 E, Kinematica, Luzern, Switzerland), incubated for 5 min 
at RT and centrifuged at 12,000 g for 10 min at 4°C.
The supernatant was mixed with 250 µl chloroform, vortexed 
for 30  s, incubated at RT for 15  min, centrifuged at 12,000  g 
for 15 min at 4°C and the aqueous phase recovered. RNA was 
precipitated by adding 125  µl isopropanol and 125  µl of high 
salt precipitation solution (0.8 M sodium citrate, 1.2 M sodium 
chloride), washed with 500 µl of 75% ethanol and dissolved in 
25  µl RNase free water after complete removal of ethanol. The 
quantity of the isolated RNA was determined spectroscopically 
(NanoDrop® Lite, Thermo Fisher Scientific, Wilmington, DE, 
USA) and the quality confirmed by the sample’s OD 260/280 
(1.8–2.0; samples with lower quality were excluded from fur-
ther analyses). cDNA was prepared using the TaqMan Reverse 
Transcription kit (TaqMan® Reverse Transcription Reagent, Life 
Technologies, Van Alben Way, CA, USA) according to the manu-
facturer’s instruction. RT-qPCR was conducted on the CFX96 
Touch qPCR Machine (Bio-Rad Laboratories, Hercules, CA, 
USA) as previously described (46, 47), by mixing 5 µl of TaqMan® 
Fast Advanced Master Mix (Life Technologies, Van Alben Way, 
CA, USA) with 10 ng cDNA in RNAse free water (4.5 µl in total) 
and 0.5  µl of canine TaqMan primers/probes (TaqMan® Gene 
Expression Assays, Life Technologies, Van Alben Way, CA, USA) 
(Table 2).
Each sample was run in duplicate for each gene, the CT value 
means were calculated and the comparative CT method was used 
for data evaluation [relative quantification (RQ)]. Samples with 
gene expression lower than the detection limit were attributed 
an artificial maximal CT value of 43, using the selection of the 
median as aggregation method between samples with the same 
experimental condition to avoid statistical and mathematical 
issues (72).
For group comparisons between H, NH, NA, and C, results 
were calculated as 2−ΔCT values, i.e., the expression of each target 
gene was normalized relative to the expression of the house keep-
ing gene [canine TATA box-binding protein (TBP)], using the 
classical ΔCT method and the following algorithm:
 RQ = 2 identically for NH, NA,
( )Ct H  Ct HTargetGene TBP− ( ) ( )− (  C).  
For interdonor calculations, an additional normalization step 
(ΔΔCT) was performed (ΔCT of H or NH minus ΔCT of NA, 
of the same animal). Results were calculated as 2−ΔΔCT values and 
shown as fold change in expression between affected discs (H, 
NH) and internal control discs (NA). The following algorithm 
was used:
 RQ = 2
[( ) (Ct H Ct H  Ct NA Ct NTargetGene TBP TargetGene− − − −( ) ( ) ( ) ( A )]TBP identically for NH) ( ). 
The intra-assay CV was 0.74% (n = 131).
Total Protein and elisa
ELISA samples were weighed and pulverized as described above, 
but with immersion in T-PER reagent (Tissue Protein Extraction 
Reagent, Thermo Fisher Scientific, Wilmington, DE, USA) at a 
ratio of 100 µl T-PER reagent per 10 mg tissue. The lysates were 
homogenized and purified following a standardized protocol. 
Briefly, samples were centrifuged at 12,000 g at 4°C for 10 min, 
the supernatant was collected and total protein was determined 
by the Bradford assay (Bio-Rad Protein Assay Dye Reagent 
Concentrate, Bio-Rad Laboratories, Hercules, CA, USA), with 
absorbance measurement at 585  nm (Infinite® 200 Pro, Tecan 
Group Ltd., Männedorf, Switzerland). The protein levels of IL-1β, 
IL-6, IL-8, and TNF-α were detected with canine specific ELISAs 
(MyBioSource, San Diego, CA, USA for IL-1β, IL-6, IL-8, and 
Quantikine ELISA Kit, R&D Systems Inc., Minneapolis, MN, 
USA, for TNF-α) according to the manufacturer’s instructions, 
with a sensitivity of 1  pg/ml for IL-1β, IL-6, and IL-8 kit and 
TaBle 3 | Detailed antibody information.
Marker Provider Order nr. Dilution read-out
CD18 P. Moore CA16.3C10 1:10 Cell infiltration
CD3 Dako A0452 1:600
vWF8 Dako M0616 1:400
p-JNK Cell Signaling 
Technologies
PA5-21343 1:50 MAP kinase 
activation
p-p38 Cell Signaling 
Technologies
ab32142 1:50
p-ERK1/2 Cell Signaling 
Technologies
MAI-13041 1:50
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4.2 pg/ml for TNF-α. Sample concentration was calculated based 
on a standard curve and normalized to total protein content. 
Results are demonstrated either as group comparisons (H, NH, 
NA, C: cytokine content/total protein in pg/mg) or as interdonor 
comparisons (H and NH relative to NA: fold change). The median 
intra-assay CV is 9.0% (range 5.3–15%) and the median interas-
say CV 10.8% (range 9.3–15%), as provided by the supplier.
immunohistochemistry
Serial sections were deparaffinized, heat-mediated antigen 
retrieval was conducted (95°C, 20  min) and sections were 
incubated with primary antibodies (RT, overnight) identifying 
infiltrating cells (polymorphonuclear, mononuclear, mac-
rophages, multinucleated giant cells) and MAP kinase (MAPK) 
pathway activation (Table 3). Subsequently, sections were treated 
with an appropriate primary antibody (Marker) and washed 
3× with Tris buffer before the secondary antimouse IgG was 
applied (1:200 dilution, 30  min). The amino-9-ethyl-carbazole 
substrate kit (Dako) was employed as a chromogen. Finally, the 
sections were counter-stained with Gill’s hematoxylin for 3 min, 
and cover-slipped with an aqueous mounting media (Glicerine, 
Sigma-Aldrich).
All slides were examined and semiquantitatively evaluated 
independently by two investigators for infiltrating cell types in the 
extruded NP as well as activation of the MAPK pathway [c-Jun 
NH2-terminal kinase (JNK), p38 isoforms of MAPK (p-38), 
extracellular signal-regulated kinases (ERKs)]. The following 
grades were used: (−) negative; (±) weakly (less than 5% of cells 
positive); (+) moderately (5–25% of cells positive); (++) strongly 
(more than 25% of cells positive).
statistical analysis
For all results, an outlier calculation was performed and outliers 
removed before statistical analysis (MedCalc 16.8/2016, http://
www.medcalc.org). Summary statistics were performed and 
normality assessed using D’Agostino-Pearson tests. As data were 
versatile regarding its distribution, nonparametric statistics 
were additionally used except for the interdonor comparison. 
A Kruskal–Wallis test was used to identify any association 
between gene and protein expression of cytokines with location 
of IVDH, duration of clinical signs, neurologic grade, pretreat-
ment and outcome. Differences in gene or protein expression of 
cytokines between the samples of affected and control animals 
were evaluated using a Mann–Whitney U-test. The subgroup 
comparison was carried out stepwise by a Wilcoxon signed-rank 
test. The Bonferoni p-value adjustment was used to control for 
multiple comparisons. For inter-donor comparisons of gene and 
protein expression, an independent sample t-test and a Mann–
Whitney U-test was performed, respectively. A Spearman’s rank 
correlation was used to examine the relationship between gene 
expression and protein level. Threshold value for statistical 
significance was set up to p <  0.05 and data are presented as 
boxplots, with median and 95% confidential interval (CI) unless 
otherwise stated.
resUlTs
clinical Data
Twenty-five dogs with surgically confirmed thoracolumbar 
IVDH were included in the study. All canine patients (25 of 
25 cases) were small and medium-breed dogs (<20  kg) with a 
median body weight at admission of 9.0 kg (range 3.6–19.0 kg). 
The dogs were classified as chondrodystrophic breeds with the 
Dachshund (n =  5), Cocker Spaniel, Coton de Tuléar and the 
French Bulldog (each n = 2) and the Bichon Frisé, Cavalier King 
Charles Spaniel, Jack Russel Terrier, Pekingese, Miniature Poodle, 
Pug Dog, Shi-Tzu, and the Yorkshire Terrier (each n = 1) or as 
non-chondrodystrophic or mixed breeds with the Border Collie 
(n = 1) and the Mixed Breed Dog (n = 5) (57, 73, 74). The median 
age was 5 years (range 3–13 years). Sixteen dogs were male intact, 
four were female intact, three were female spayed, and two were 
male castrated. The median duration of clinical signs until sur-
gery was 3 days (range 1–365 days). When classified into three 
groups, there were 3 acute, 14 subacute, and 8 chronic cases. Ten 
dogs were referred without pretreatment, five had been pretreated 
with steroids, seven with NSAIDs, and three with a combination 
of both, pooled together as pretreated dogs. The neurologic status 
before surgery was Grade 2 in 11, Grade 3 in 6, Grade 4 in 5, and 
Grade 5 in 5 dogs. Pain score revealed 2 dogs with Grade 0, 14 
dogs with Grade 1, and 9 animals with Grade 2. The spinal level of 
IVDH in the affected dogs were L2–L3 in eight dogs, Th12–Th13 
in six dogs, Th11-Th12, L1–L2, L3–L4 in each three dogs, and 
Th10–Th11, Th13–L1 in each one dog. Fifteen dogs had a good 
outcome, six showed an improvement, but were not ambulatory, 
and four showed no improvement within 1 month after surgery. 
In the latter case, two of them were euthanized because of poor 
prognosis, a follow-up call unveiled that the other two dogs are 
still in physiotherapy treatment showing no improvement in the 
last 7 and 9 months.
Eleven euthanized dogs without signs of IVDH were included 
as control group. The median age of the control group was 4.5 years 
(2–11 years). Ten dogs were female spayed and one dog was female 
intact. There were 10 beagles and 1 was a mixed breed dog.
Diagnostic imaging and surgical 
Treatment
All 25 affected dogs underwent surgical decompression of the 
spinal cord immediately after diagnostic imaging, including 
the collection of the samples. Three different samples (H, NH, 
and NA) were collected in 14 dogs, two different samples (H, 
FigUre 1 | Gene expression of IL-6 in herniated disc material, compared 
between dogs with differing grade of pain (n = 11) and shown as 2−ΔCT. 
Grade 1 = no spontaneous pain, but discomfort upon palpation of the spine. 
Grade 2 = spontaneous pain and excessive pain upon palpation of the spine. 
Asterisks indicate statistical significance between groups at p < 0.05 (*).
TaBle 4 | Statistical results of gene expression data (subgroup comparison, independent samples).
cytokine control iVD Median (95% ci) comparative iVD Median (95% ci) p-Value
IL-1β C 10.556 (5.927–27.650) H 1.798 (0.329–7.156) 0.018
IL-6 C 0.012 (0.004–0.052) H 0.057 (0.034–0.139) 0.013
NH 0.178 (0.045–1.114) 0.006
TNF-α C 0.007 (0.001–0.022) H 0.112 (0.036–0.230) 0.008
NA 0.087 (0.024–0.186) 0.008
NH 0.060 (0.019–0.080) 0.007
5
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NH) in 6 dogs, and one sample (H) in 5 dogs, resulting in a total 
of 59 samples. The median sample weight was 30.62 mg (range 
1.7–112.3 mg). Six disc samples were excluded: four NHs and 
one H were excluded due to very small size and one NH sample 
demonstrated inconsistent housekeeping gene expression and 
out of range protein values. From the remaining 53 samples, 
11 tissue samples weighting more than 50  mg were equally 
divided in samples for PCR and ELISA testing. 18 smaller 
samples were solely assigned to PCR testing and 24 smaller 
samples solely to ELISA testing. In the C group, we collected 
11 samples in 11 dogs in the Th13–L1–L2 IVD space, with a 
median sample weight of 60.87 mg (range 30.3–133 mg). One 
dog was completely omitted because of RNA impurity. From 
the 10 remaining control samples, 4 samples weighting more 
than 50 mg were equally split into samples for PCR and ELISA. 
Three samples each were solely assigned to PCR and ELISA 
testing.
cytokine Detectability
We could demonstrate gene and protein expression of the 
selected proinflammatory cytokines IL-1β, IL-6, IL-8, and TNF-α 
in IVDH in dogs.
gene expression
No significant correlation between IVDH location, duration of 
clinical signs or outcome, and the genes of interest was demon-
strated, but the gene expression of IL-6 was significantly higher 
(p =  0.043) in pain grade 2 compared to grade 1 (Figure  1). 
Pooled results of all dogs in the respective groups (C, H, NH, NA) 
showed a significant downregulation of IL-1β in H compared to 
C, but no difference between NH or NA and C was found. IL-6 
expression was significantly higher in H and NH compared to 
C, but not in NA. TNF-α expression showed significantly higher 
levels in H, NA, and NH compared to C. Gene expression of IL-8 
showed no significant difference among the groups. All results are 
shown in Table 4 and Figure 2.
As patients demonstrated differences in their basal cytokine 
levels, hence resulting in high donor–donor variations in sub-
group comparisons, an interdonor comparison was conducted 
(H and HN relative to NA = internal control for each patient). A 
significant increase of IL-6 was observed for H and NH compared 
to NA. In contrast, gene expression of IL-1β, IL-8, and TNF-α 
were either unchanged or reduced in diseased compared to NA 
IVDs. All results are shown in Table 5 and Figure 3.
Protein expression
There were no significant correlations between cytokine protein 
levels and IVDH location, severity of pain, pretreatment or out-
come and concentration of cytokines, but IL-6 was found to be 
significant higher in the clinical outcome group 2 compared to 
group 1 (Figure 4).
No significant differences of IL-1β or IL-6 protein expression 
were observed between the various groups. The concentration of 
IL-8 was significantly higher in H and NA compared to C, but 
no difference was found between NH and C. TNF-α showed 
significantly higher protein levels in NH compared to C, but not 
for H or NA. Results are shown in Table 6 and Figure 5.
Like for gene expression, an additional inter-donor compari-
son was conducted, with NA as the internal control. However, no 
statistical differences were found between diseased (H, NH) and 
NA IVDs due to a level of variability and low sample numbers 
(data not shown).
No significant relationship was found between gene expres-
sion and corresponding protein concentration (IL-1β rs = 0.02; 
95% CI, −0.66–0.67, p = 0.97; IL-6 rs = 0.30; 95% CI, −0.41–0.78; 
p = 0.41; IL-8 rs = −0.25, 95% CI, −0.85–0.62, p = 0.59; TNF-
α rs = −0.51, 95% CI, −0.86–0.18, p =  0.13). Interestingly, a 
significant association in gene expression between IL-6 and IL-8 
(rs = 0.79, 95% CI 0.08–0.97, p = 0.036) was found in the control 
TaBle 5 | Statistical results of interdonor gene expression data (subgroup comparison, dependent samples).
cytokine control iVD comparative iVD Median (95% ci) p-Value
IL-6 NA H 498.625 (3.722–20,901.118) 0.031
NH 2,473.292 (158.129–43,724.429) 0.031
FigUre 2 | Gene expression data (subgroup comparison, independent samples, n ≥ 6 per subgroup) of (a) IL-1β, (B) IL-6, (c) IL-8, and (D) TNF-α, compared 
between herniated (H), non-herniated (NH), non-affected (NA) as well as healthy control (C) intervertebral disc material. Data are shown as 2−ΔCT. Asterisks indicate 
statistical significance between groups at p < 0.05 (*) and p < 0.01 (**).
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group. In herniated samples, IL-1β protein correlated with IL-6 
(rs = 0.71; 95% CI, 0.36–0.88, p = 0.001), IL-8 (rs = 0.54; 95% CI, 
0.09–0.80, p = 0.02) as well as TNF-α concentrations (rs = 0.55; 
95% CI, 0.11–0.81, p = 0.02) measured by ELISA.
immunohistochemistry
Monocytes and macrophages were the most infiltrating cell 
population encountered in canine herniated IVD material. 
Sporadically, giant cells resembling notochordal cells were 
observed. CD 18 was highly expressed (++) in all samples, 
whereas detection of CD3 and vWF8 detection was semi-
intractable and error-prone, hence not being shown. Expression 
of activated (phosphorylated) ERK (++) (Figure  6) and p38 
(+/++) could be detected in most of the examined slides, 
whereas pJNK (−/+) was only sporadically detectable (not 
shown).
FigUre 4 | Protein expression of IL-6 in herniated disc material, compared 
betwen dogs with differing clinical outcome (n = 20) and shown as 
picogram of IL-6 per milligram total protein. Grade 0 = lack of 
improvement. Grade 1 = improvement of neurologic status, but not able to 
walk. Grade 2 = recovery of ambulation or at least one grade in neurologic 
grades 1 and 2. Asterisks indicate statistical significance between groups 
at p < 0.05 (*).
FigUre 3 | Fold change in IL-6 gene expression (interdonor comparison, 
n = 6 per subgroup) between each dog’s non-affected IVD material (NA)  
and the same dog’s herniated (H) or non-herniated (NH) intervertebral disc 
material. Data are shown as 2−ΔΔCT. Asterisks indicate statistical significance 
between groups at p < 0.05 (*).
TaBle 6 | Statistical results of protein expression data (subgroup comparison, independent samples).
cytokine control iVD Median (95% ci) comparative iVD Median (95% ci) p-Value
IL-8 C 0.00001 (0.00001–0.00001) H 3.925 (0.00001–17.823) 0.012
NA sufficient 126.294 (13.728–187.946) 0.035
TNF-α C 0.00001 (0.00001–0.00001) NH sufficient 0.00001 (0.00001–9.924) 0.042
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DiscUssiOn
Previous research on human IVD tissue has demonstrated that 
degeneration and herniation coincides with increased levels of 
inflammatory mediators, such as IL-1β, IL-6, IL-8, and TNF-α 
(8). In the present study, a comparison between diseased (herni-
ated IVDs = H; NH) and control (C) IVDs of dogs demonstrated 
that disc disease was associated with significantly higher gene 
expression of IL-6 (H vs. C, NH vs. C) and TNF-α (H vs. C, NH 
vs. C). On the protein level, a significant increase of IL-8 and 
TNF-α in IVDs of diseased dogs compared to controls was found. 
A patient-specific comparison between the diseased (H, NH) and 
the IVDs excised from an adjacent level (NA) of the same dog 
revealed a pronounced pathological elevation of IL-6 (H vs. NA, 
NH vs. NA). In contrast, mRNA levels of IL-1β, IL-8, and TNF-α 
were either unchanged or reduced in diseased compared to NA 
IVDs of patients.
Previous studies on canine disc disease found IL-1β to be 
either undetectable or downregulated in dogs, which contrasts 
human disc pathology (64, 75). This was confirmed by our find-
ings, showing a significant downregulation of the gene expression 
of IL-1β in herniated disc material (H) compared to controls, 
a downregulation in the affected disc material (H, NH) of the 
paired samples and no significant findings on the protein level.
In human IVDH, higher protein levels of the proinflamma-
tory cytokine IL-6 were detected in different studies (10, 23, 25, 
76), hence being discussed as a prognostic factor and therapeutic 
target. Thus far, results on IL-6 expression during canine disc 
disease are contradictory (63, 64, 75, 77). According to our find-
ings, IL-6 seems to have a pivotal role, with its gene expression 
being significantly upregulated in the affected disc material (H, 
NH) of the independent and paired samples, unrelated to the 
duration of the clinical signs. Interestingly, we noticed a correla-
tion between IL-6 mRNA levels and the severity of pain, with 
mRNA expression being significantly higher in those canine 
patients with basal pain than in those with pain arising only 
upon palpation. To the authors’ knowledge, this has not been 
described before in canine IVDH, but might be in accordance 
with recent research in humans that has increasingly pointed 
toward IL-6 being a crucial factor in pain development (78, 
79). However, IL-6 is not only a proinflammatory cytokine with 
significance in inflammation and diseases, but is also known to 
have regenerative or anti-inflammatory properties (80). Our 
results indicated that canine patients showing higher concentra-
tion of IL-6 protein levels in their IVD had a better outcome and 
were more likely to regain ambulation. This contrasting finding 
might be explained by the dual function of IL-6, suggesting that 
with time, IL-6 might control inflammation by acting as an anti-
inflammatory cytokine (81, 82). IL-6 originates directly from 
FigUre 5 | Protein expression data (subgroup comparison, independent samples, n ≥ 6 per subgroup) of (a) IL-1β, (B) IL-6, (c) IL-8, and (D) TNF-α, compared 
between herniated (H), non-herniated (NH), non-affected (NA) as well as healthy control (C) intervertebral disc material. Data are shown as picogram of each 
cytokine per milligram total protein. Asterisks indicate statistical significance between groups at p < 0.05 (*).
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IVD cells (76) and also from T-cells and macrophages (83–86), 
the latter constituting the main cell population of the inflamma-
tory infiltrates in the epidural space after IVD extrusion in our 
samples. Based on our findings, IL-6 could potentially have also 
a beneficial role in the late onset of the inflammatory cascade of 
canine IVDH. Therefore, therapeutic blockage for IL-6 should 
be carefully considered.
In this study, we also analyzed the expression of IL-8, which 
has previously been shown to be strongly upregulated in the 
acute phase of canine IVDH (63, 64, 77), yet with a negative cor-
relation between its expression and the duration of spinal cord 
injury secondary to IVDH (77). As IL-8 is thus thought to be 
an early disease marker with time-dependent expression and as 
our patients were mostly seen for treatment at a late stage of the 
disease, it explains why we could not demonstrate a significant 
upregulation of IL-8 mRNA, but of IL-8 protein in diseased discs. 
Interestingly, a significant upregulation of the protein level of IL-8 
in independent samples could as also be demonstrated in NA disc 
material, suggesting a possible secretion of IL-8 in canine disc 
material before the effective herniation of the affected IVD and 
hence further supporting a possible early stage inflammation as 
a trigger for IVDH.
Together with IL-1β, TNF-α is likely the most studied cytokine 
in human IVDD (11, 17, 28, 87, 88), inducing matrix degrading 
enzyme expression and upregulation of nerve growth factor. 
TNF-α is hence suggested to be have an important role in the 
development of hyperalgesia and chronic pain after IVDH in 
humans (7, 16, 28, 89–92). Contradictory results have been 
found on TNF-α expression in canine IVDH, ranging from 
non-detectability (64, 75, 77) to disease-related elevation (albeit 
non-significant) (63). In accordance with Spitzbart et al. (63), as 
well as with human studies, we could demonstrate a significant 
FigUre 6 | Immunohistochemical staining for extracellular signal-regulated kinase (ERK)1/2 of extruded canine intervertebral disc material (left). Expression of ERK 
(brownish coloration) was detected in the majority of the examined slides. On the right, negative control and positive control (canine mammar carcinoma) are 
depicted.
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upregulation of TNF-α on the gene expression level (H, NH) and 
the protein expression level (NH). Furthermore, and also similar 
to human NP samples in which TNF-α is known to be continu-
ously expressed at basal levels (93), TNF-α could also be detected 
in adjacent discs (NA) suggesting to be a possible trigger of an 
early stage inflammation for IVDH.
Histological investigations demonstrated that most herniated 
IVDs exhibited an epidural inflammatory response, ranging from 
acute invasion of neutrophils to formation of chronic granula-
tion tissue. Histological analysis of underlying inflammatory 
pathways demonstrated activation of the MAPKs ERK and p38 
in most samples, whereas pJNK was rarely detected. MAPKs are 
signal transduction pathways that are activated by a multitude 
of stimuli, ranging from environmental, mechanical and osmotic 
stress to growth factors, cytokines and reactive oxygen species, 
with ERK and p38 controlling inflammation, catabolism as well 
as cell growth, differentiation and viability/death (27). The fact 
that the MAPKs pathways are shared between the cytokines 
might explain the correlation on the protein level in herniated 
samples of IL-1β with IL-6, IL-8, and TNF-α (94).
In accordance with our results, in vitro cell culture studies and 
rodent in  vivo studies have previously demonstrated that p38 
and ERK are activated in inflammatory environments (95–100), 
controlling a variety of metabolic functions associated with 
disc pathology, including proteoglycan degradation (96, 97). 
Furthermore, the decrease in osmotic pressure observed during 
herniation in our canine patients may also play a causative role 
in MAPK activation as previously demonstrated for bovine IVDs 
and the ERK pathway (101). Importantly, activation of p38 and 
ERK in our canine samples may not only induce downstream 
expression of additional inflammatory mediators and matrix 
degrading enzymes and hence play an important role in disease 
progression [reviewed in Ref. (27)], but may furthermore be a 
means to initiate resorption of non-contained herniated disc 
tissue (102–104).
Despite providing interesting new findings on the inflamma-
tion in canine IVDH, the present study has several limitations that 
should be considered. The dog size as well as the morphologic size 
of the herniated disc tissue imposed limitations on the number 
of performed tests. The quantity of surgically excised canine disc 
material is smaller than specimens collected in humans. Therefore, 
we could not divide all samples equally for PCR and ELISA test-
ing as planned in the study design, resulting in variations in group 
size. Due to the non-predictable onset of canine IVDH, the group 
could neither be age nor gender matched, possibly influencing 
the results. Furthermore, most of our patients were presented at 
a late stage of the disease, which may explain why we might have 
missed the peak expression of some cytokines in the acute stage 
of the disease.
cOnclUsiOn
Inflammation in the epidural compartment plays a central role in 
the pathophysiology of canine IVD herniation and significantly 
influences the course and outcome of the disease. Working 
with a clinical canine model not only provides the possibility to 
overcome animal experimentation, but furthermore allows (dif-
ferent from human studies) the analysis of adjacent, NA discs. 
Although expression of key cytokines found in human IVDs 
could also be demonstrated in canine tissue, the inflammatory 
mechanisms accompanying IVDH in dogs partially diverge from 
humans. These differences need to be considered when using 
dogs as a model for human medicine. In dogs, IL-6 seems to play 
an important pathological role, but further investigations on IL-6 
as a potential therapeutic target in canine patients will be needed, 
especially when considering its likely ambivalent role.
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